Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 2/20 | 0.63 |
| ▸ | CCR8 | P51685 | 2/20 | 0.63 |
| ▸ | CCR5 | P51681 | 1/20 | 0.63 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.51 |
| ▸ | MEN1 | O00255 | 5/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.51 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | IDO1 | P14902 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.45 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.45 |
| ▸ | AURKA | O14965 | 1/20 | 0.45 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31553579 | 0.80 | CCR1 (0.71) | CCR1CCR8CCR5NR4A2KDM4E | |
| SCHEMBL21625616 | 0.79 | KDM4E (0.75) | CCR1CCR8CCR5KDM4EKMT2A | |
| SCHEMBL516559 | 0.79 | CCR1 (0.63) | CCR1CCR8CCR5KDM4EKMT2A | |
| SCHEMBL9034116 | 0.79 | CCR1 (0.69) | CCR1CCR8CCR5NR4A2KDM4E | |
| SCHEMBL3829932 | 0.79 | CCR1 (0.63) | CCR1CCR8CCR5KDM4EKMT2A | |
| SCHEMBL23760627 | 0.79 | CCR1 (0.63) | CCR1CCR8CCR5NR4A2KDM4E | |
| SCHEMBL1088410 | 0.78 | CCR1 (1.00) | CCR1CCR8CCR5KDM4EKMT2A | |
| SCHEMBL6538409 | 0.78 | TYK2 (0.51) | CCR1CCR8CCR5KDM4EKMT2A | |
| SCHEMBL318769 | 0.77 | NR4A2 (0.68) | CCR1CCR8NR4A2KDM4EKMT2A | |
| SCHEMBL29410781 | 0.77 | NR4A2 (0.68) | CCR1CCR8NR4A2KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100022570-A1 | NOVEL MICROBIOCIDES | SYNGENTA CROP PROTECTION, INC. (US) | 2010-01-28 | — | — | US | disclosed |
| US-20100022570-A1 | NOVEL MICROBIOCIDES | SYNGENTA CROP PROTECTION, INC. (US) | 2010-01-28 | — | — | US | disclosed |
| EP-2018367-B1 | NOVEL MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2009-11-18 | — | — | EP | disclosed |
| EP-2018367-A1 | NOVEL MICROBIOCIDES | Syngeta Participations AG (CH) | 2009-01-28 | — | — | EP | disclosed |
| WO-2007134799-A1 | NOVEL MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2007-11-29 | — | — | WO | disclosed |
| WO-2007134799-A1 | NOVEL MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2007-11-29 | — | — | WO | disclosed |
| CN-1025854-C | Process for preparing quinolyl oxazol-2-ones | MERRELL DOW PHARMA (US) | 1994-09-07 | — | — | CN | disclosed |
| EP-0365863-B1 | Novel quinolyloxazole-2-ones useful as proteinkinase C inhibitors | MERRELL DOW PHARMA (US) | 1994-08-17 | — | — | EP | disclosed |
| EP-0428105-B1 | Use of quinolyl- and isoquinolyloxazole-2-ones for the production of a medicament for the prevention of glycoprotein enveloped virus infectivity | MERRELL DOW PHARMA (US) | 1994-01-19 | — | — | EP | disclosed |
| EP-0428107-B1 | Use of quinolyl-and isoquinolyloxanole-2-ones for the production of a medicament for the treatment of multi-drug resistant tumors | MERRELL DOW PHARMA (US) | 1994-01-19 | — | — | EP | disclosed |
| US-5190957-A | TREATMENT OF MULTI-DRUG RESISTANT TUMORS WITH QUINOLYL-AND ISOQUINOLYLOXAZOLE-2-ONES | MERRELL DOW PHARMACEUTICALS INC. (US) | 1993-03-02 | — | — | US | disclosed |
| US-5061715-A | Useful in treating AIDS and ARC | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-10-29 | — | — | US | disclosed |
| EP-0428107-A2 | Use of quinolyl-and isoquinolyloxanole-2-ones for the production of a medicament for the treatment of multi-drug resistant tumors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-05-22 | — | — | EP | disclosed |
| EP-0428105-A2 | Use of quinolyl- and isoquinolyloxazole-2-ones for the production of a medicament for the prevention of glycoprotein enveloped virus infectivity | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-05-22 | — | — | EP | disclosed |
| US-4999431-A | Reacting A Bromoquinoline Compound With Butyllithium And An N-Methyl-N-Methoxyalkanamide; Intermediates for Quinolyloxazole-2-ones | MERRELL DOW PHARMACEUTICALS (US) | 1991-03-12 | — | — | US | disclosed |
| US-4990519-A | Antiasthma, hypotensive agents, bronchodilator agents | MERRELL DOW PHARMACEUTICALS (US) | 1991-02-05 | — | — | US | disclosed |
| CN-1042145-A | New quinolyl azoles-2-ketone compounds as inhibitors of protein kinase C | MERRELL DOW PHARMA (US) | 1990-05-16 | — | — | CN | disclosed |
| EP-0365863-A2 | Novel quinolyloxazole-2-ones useful as proteinkinase C inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-05-02 | — | — | EP | disclosed |
| US-4886811-A | HYPOTENSIVE AGENTS AND VASODILATORS | MERRELL DOW PHARMACEUTICALS (US) | 1989-12-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022570-A1 | NOVEL MICROBIOCIDES | QSOX1, MSR1, NOX1 | CCR1 56/4885CCR8 309/4885CCR5 248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.